15th Edition R&D and Innovation Excellence Forum

Transform R&D with AI and Market-Ready Innovation to Maximize ROI and Business Impact

The marcus evans15^th Edition R&D and Innovation Excellence Forum taking place on 4-6 February, 2026, in New Jersey, will bring together key industry leaders to explore the latest strategies to optimise investments, streamline decision-making, and accelerate transformation in R&D. This event is your gateway to understanding how to drive efficiency, foster cross-functional collaboration, and refine R&D processes to stay ahead in an increasingly competitive landscape. Don't miss out on this opportunity to empower your R&D team with the tools and knowledge to thrive in a rapidly evolving market.

Attending This Premier marcus evans Conference Will Enable You to:

• AchieveOperational Excellence in a Global R&D Organization
• MeasureObjectives to support Resource Allocation in R&D
• AssessMethods for Aligning Costs with Organisational Value and Strategic Objectives
• DevelopStrategies for Allocating Resources Effectively to Optimise R&D projects
• Selectthe Right Methodologies for Project Prioritisation and Value Assessment
• DevelopR&D Plans for Future Success and Implementing Risk Management Strategies

Best Practices and Case Studies from:

• Daniel Rich, Vice President, Growth Strategy & New Product Development, Mastercard
• Gunther Lenz,VP Software R&D, BD Biosciences
• Vatsala Sadasivan,Head of Operational Excellence, R&D, Sanofi
• Thomas J McNally, Head of Program Management Office, Bayer
• Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology, IDC
• Flavia Magalhaes, Finance Director R&D, GSK

Innoget members are entitled to $200 discount! For more information please contact: Ria Kiayia, Digital Media and PR Marketing Manager at riak@marcusevanscy.com or visit: https://tinyurl.com/5npa633x

• Topics

• Agriculture and marine resources
• Agrofood industry
• Energy
• Blockchain
• Industrial manufacturing and materials transport
• Medical / Health related
• Social and economic concerns
• Pharmaceuticals
• Fintech